Vor Biopharma Inc. Tax Withholding Paid on Stock Awards
Vor Biopharma Inc. (VOR) reported Tax Withholding Paid on Stock Awards of $4.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $2.00K, a 93.75% decline year-over-year.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $2.00K, a 96.36% decline year-over-year.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $148.00K, a 393.33% increase year-over-year.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $19.00K, a 72.86% decline year-over-year.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $254.00K, a 23.72% decline from fiscal 2024.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $333.00K, a 71.95% decline from fiscal 2023.
- Vor Biopharma Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $1.19M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.00K 10-Q · filed 2026-08-11 | $152.00K derived: sum of 3 quarters · filed 2026-08-11 | $171.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-13 | $150.00K derived: sum of 2 quarters · filed 2026-05-13 | $169.00K derived: sum of 3 quarters · filed 2026-05-13 | $201.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $167.00K derived: sum of 2 quarters · filed 2026-03-30 | $199.00K derived: sum of 3 quarters · filed 2026-08-11 | $254.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $51.00K derived: sum of 2 quarters · filed 2026-08-11 | $106.00K 10-Q · filed 2025-11-13 | $136.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $87.00K 10-Q · filed 2026-08-11 | $117.00K derived: sum of 3 quarters · filed 2026-08-11 | $187.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $55.00K 10-Q · filed 2026-05-13 | $85.00K derived: sum of 2 quarters · filed 2026-05-13 | $155.00K derived: sum of 3 quarters · filed 2026-05-13 | $206.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $100.00K derived: sum of 2 quarters · filed 2026-03-30 | $151.00K derived: sum of 3 quarters · filed 2026-03-30 | $333.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $121.00K derived: sum of 2 quarters · filed 2025-11-13 | $303.00K 10-Q · filed 2025-11-13 | $325.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $233.00K 10-Q · filed 2025-08-12 | $255.00K derived: sum of 3 quarters · filed 2025-08-12 | $475.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $182.00K 10-Q · filed 2025-05-14 | $204.00K derived: sum of 2 quarters · filed 2025-05-14 | $424.00K derived: sum of 3 quarters · filed 2025-05-14 | $969.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $242.00K derived: sum of 2 quarters · filed 2025-03-20 | $787.00K derived: sum of 3 quarters · filed 2025-03-20 | $1.19M 10-K · filed 2025-03-20 |
| 2023-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $765.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.17M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $545.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $945.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |